Analysts take a look at Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) having this to say.

February 15, 2018 - By Linda Rogers

 Analysts take a look at Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) having this to say.
Investors sentiment decreased to 1.36 in Q3 2017. Its down 0.10, from 1.46 in 2017Q2. It dived, as 5 investors sold Idera Pharmaceuticals, Inc. shares while 20 reduced holdings. 11 funds opened positions while 23 raised stakes. 46.97 million shares or 1.60% more from 46.23 million shares in 2017Q2 were reported.
Citigroup stated it has 0% of its portfolio in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). New York-based Morgan Stanley has invested 0% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Baker Bros Advsrs Limited Partnership stated it has 0.19% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). California Pub Employees Retirement System holds 160,600 shares or 0% of its portfolio. Panagora Asset stated it has 7,856 shares or 0% of all its holdings. Susquehanna Intll Group Limited Liability Partnership accumulated 38,676 shares. Moreover, Jpmorgan Chase has 0% invested in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Millennium Mngmt Limited Liability Company holds 1.63 million shares. Citadel Advisors Ltd Liability owns 23,050 shares. 3.16 million are held by Natixis. State Common Retirement Fund owns 78,200 shares for 0% of their portfolio. Bnp Paribas Arbitrage Sa holds 0% or 10,848 shares. Leavell Mngmt reported 0.02% of its portfolio in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Barclays Public Ltd, a United Kingdom-based fund reported 53,786 shares. Moreover, Alyeska Investment Grp Inc Limited Partnership has 0.01% invested in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA).

Since October 26, 2017, it had 1 insider buy, and 2 selling transactions for $7.00 million activity. 8.00 million shares were bought by BAKER BROS. ADVISORS LP, worth $12.00 million.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ratings Coverage

Among 4 analysts covering Idera Pharma (NASDAQ:IDRA), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Idera Pharma had 7 analyst reports since January 6, 2016 according to SRatingsIntel. Wedbush maintained the stock with “Outperform” rating in Wednesday, February 1 report. The firm has “Buy” rating by Piper Jaffray given on Thursday, November 9. As per Thursday, November 16, the company rating was maintained by H.C. Wainwright. The stock of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) has “Buy” rating given on Monday, September 11 by Piper Jaffray. The rating was initiated by Wedbush with “Outperform” on Wednesday, January 6. Below is a list of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) latest ratings and price target changes.

16/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $4.0 Maintain
09/11/2017 Broker: Piper Jaffray Rating: Buy New Target: $4.0 Maintain
09/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $4 Initiates Coverage On
11/09/2017 Broker: Piper Jaffray Rating: Buy New Target: $4.0 Maintain

The stock decreased 4.50% or $0.09 during the last trading session, reaching $1.91. About 552,937 shares traded. Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) has risen 21.13% since February 15, 2017 and is uptrending. It has outperformed by 4.43% the S&P500.

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. The company has market cap of $373.66 million. It uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense technology. It currently has negative earnings. The companyÂ’s drug candidates include IMO-2125, an agonist that is in Phase I/II clinical trials in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma and refractory solid tumors; IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis.

More recent Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) news were published by: which released: “BioCryst Pharmaceuticals and Idera Pharmaceuticals Announce Merger to Combine …” on January 22, 2018. Also published the news titled: “Bragar Eagel & Squire, PC is Investigating the Board of Directors of Idera …” on January 22, 2018.‘s news article titled: “Why II-VI, Sanmina, and Idera Pharmaceuticals Slumped Today” with publication date: January 22, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.